Ryzodeg Quiz

Improvement in TIR are predict the reduce the incidence of diabetic complications.

• True

• False

The primary endpoint in all of the phase 3a clinical trials of IDegAsp was ______________.

• Change from baseline in FPG

• Change from baseline in PPG

• Change from baseline in HbA1c

• Change from baseline in Insulin dose

As per BOOST trial programme, confirmed hypoglycaemia is defined as blood glucose levels lesser than _________ mg/dl.

• 60

• 72

• 50

• 56

As per BOOST trial programme, for nocturnal hypoglycaemia, time is specified as:

• 12:01am – 07:59am

• 12:01am – 05:59am

• 10:01pm – 07:59am

• 10:01pm – 05:59am

BOOST Japan OD involves patients with ___________.

• OAD Failure Patinets

• Basal Failure Patients

• Premix failure patniets

Which statement is not true for TIR __________.

• Less likely to capture the impact of acute interventions.

• Evaluates continuous glucose monitoring.

• May compare the fluctuations any given amount of time.

As per BOOST Japan OD, after 26 weeks of treatment, the total insulin dose with IDegAsp was.

• 29

• 27

• 26

• 28

In BOOST Japan, IDegAsp resulted in a numerically lower rate of both confirmed (by ______%) and nocturnal confirmed (by ______%) hypoglycaemia compared with insulin glargine U100 (NS).

• 25, 27

• 27, 25

In BOOST Japan, the estimated treatment difference (ETD) in change in HbA1c after 26 weeks for IDegAsp versus insulin glargine U100 was –_______%-points, confirming _________ of IDegAsp relative to insulin glargine U100.

• 0.58%, non-inferiority

• 0.38%, inferiority

• 0.28%, superiority

• 0.28%, non-inferiority

As per ADA how much time of the day spent in TIR.

• 78%

• 70%

• 79%